spec play; bought at 28, consistently downward ever since, with occassional roller coaster flare ups.

New products pending?

PGNX - has to restart a drug trial for its constipation drug. But the
company is already making money, profits were higher than expected,
they have $125mm cash in the bank and they are down 20% from their
highs. Even the analyst who lowered his estimate for PGNX two weeks
ago has them at a $33 price.

diabetic hopeful

Upgraded by RBC Capital Mkts from Sector Perform to Outperform

Rating: BUY
Target: $35
Sector: Healthcare

Expected value drivers in 2007: (1) priority review and filing of NDA for methylnaltrexone (MNTX) for AMI in 1Q07; (2) our forecast that Adolor will continue losing ground as its drug, Entereg, suffers more delays and is ultimately terminated; (3) positive PRO 140 Phase 1b data in 2Q07;
and (4) positive MNTX Phase 3 POI data in 3Q07.